Tarsus Pharmaceuticals, Inc. TARS Finished goods
Finished goods at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s finished goods.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s finished goods?
- Tarsus Pharmaceuticals, Inc. (TARS) reported finished goods of $2.94M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s finished goods changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s finished goods increased by 51.5% year-over-year, from $1.94M to $2.94M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s finished goods?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s finished goods has grown at a 303.4% compound annual growth rate (CAGR), from $182K to $2.96M.
- What does finished goods mean?
- Completed products ready for sale, valued at the lower of cost or net realizable value.